Formulation
Development
Optimised, phase‑appropriate formulations for small molecules and live biotherapeutics. SGS helps you overcome solubility, stability and bioavailability challenges with end‑to‑end development expertise.
Bringing a pharmaceutical product from concept to clinic requires robust formulation design backed by deep scientific understanding. SGS offers specialist formulation development services for small molecules and live biotherapeutics, supporting programs from early feasibility through FIH and POC studies. Our phase‑appropriate approach ensures your formulation evolves with your program, meeting the needs of regulators and clinical partners. Any IP generated is fully retained by you as the client.
Comprehensive expertise across dosage forms
Key Benefits
From oral solids to liquids, semi‑solids, and targeted microbiome delivery systems.
Solutions for complex molecules
Specialists in low‑solubility, low‑bioavailability APIs and live biotherapeutics.
Client-owned IP
SGS operates on a fee‑for‑service model—any formulation IP remains with you.
Seamless integration with GMP manufacturing
Benefit from our flexible and comprehensive outsourcing services, designed to meet your specific needs.
Phase-appropriate development
Fit‑for‑purpose FIH / POC formulations aligned to the Quality Target Product Profile. .
Formulation Development Services
Small Molecule Formulation Development
SGS provides formulation optimisation for a wide range of small‑molecule APIs, including those with challenging physiochemical properties. Dosage form support includes:
Oral solid dose
Immediate & controlled‑release capsules
Coated capsules
Fast‑dispersible formats
Micro‑encapsulated systems
Multiparticulates (beads & pellets)
Liquid & semi‑solid filled capsules
Other dosage forms
Oral liquids & suspensions
Topical products
Parenteral formulation development (non sterile)
Live Biotherapeutic Product (LBP) Formulation
SGS is one of the few companies licensed to develop and clinically manufacture live biotherapeutic formulations. Capabilities include:
- Targeted-release oral dosage forms for improved microbiome survival
- Manufacturing process development minimising oxygen exposure
- Primary & secondary packaging tailored to shelf-life and patient requirements
- Expertise across:
Why SGS?
As a globally recognised CDMO, SGS delivers the scientific rigour, regulatory insight and development expertise required to bring innovative drug products to clinical evaluation. Our multidisciplinary teams work in MHRA‑ and FDA‑inspected facilities, providing a trusted environment for complex formulation challenges—from traditional small molecules to next‑generation live biotherapeutics. With an integrated service model spanning formulation, analytics and GMP manufacturing, we offer a streamlined pathway from concept to clinic.
